PPTA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Perpetua Resources Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, March 23, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Perpetua Resources Corp. ('Perpetua' or 'the Company') (NASDAQ: PPTA) and certain of its officers.
Class Definition
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Perpetua securities between April 17, 2024 and February 13, 2025, both dates inclusive (the 'Class Period'). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/PPTA.
Case Details
The Complaint alleges that throughout the Class Period, Defendants provided investors with material information concerning Perpetua's expected initial capital expenditure for the Stibnite Gold Project. Defendants' statements included, among other things, minimization of the impact of inflation and other potential sources for increased capital expenditure costs for the project.
On February 13, 2025, Perpetua disclosed in a filing with the U.S. Securities and Exchange Commission that the Company had 'released an updated cash flow model for the Stibnite Gold Project (the 'Project'), which is based, in part, on basic engineering work completed by Ausenco Engineering USA South Inc. ('Ausenco') in January 2025 (the 'Financial Update').' Perpetua said that the 'Financial Update also applies fourth quarter 2024 cost estimates for construction and operations, consistent with the Basic Engineering analysis, as well as current and consensus commodity pricing for sales' and that 'the Financial Model reflects an increase in initial and total capital expenditures and LOM AISC compared to the base model included in the 2020 Feasibility Study' for the Project. On this news, Perpetua's stock price fell $2.68 per share, or 22.39%, to close at $9.29 per share on February 14, 2025.
What's Next?
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/PPTA. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in Perpetua you have until May 20, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Contact
Bronstein, Gewirtz & Grossman, LLC
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indianapolis Star
41 minutes ago
- Indianapolis Star
New to The Street Episode #671 Airs Tonight on Bloomberg Television at 6:30 PM EST Featuring FLOKI, Arrive AI (NASDAQ: ARAI), Health In Tech (NASDAQ: HIT), Vita Bella, and NRX Pharmaceuticals (NASDAQ: NRXP)
This week's episode is sponsored by The Sustainable Green Team's Waterless Garden (OTC:SGTM) and PetVivo Holdings, Inc.'s (NASDAQ:PETV) innovative SPRYNG™ product. NEW YORK CITY, NY / ACCESS Newswire / June 14, 2025 / New to The Street, the nationally syndicated business television series known for spotlighting innovation across sectors, announces the premiere of Episode #671 airing tonight on Bloomberg Television at 6:30 PM EST. This week's broadcast features five dynamic companies making waves across blockchain, AI, health tech, wellness, and pharmaceutical sectors: FLOKI – The globally recognized crypto and blockchain brand building Web3 utility through its DeFi ecosystem. Arrive AI (NASDAQ:ARAI) – Developer of a patented smart mailbox delivery platform, leading last-mile logistics innovation with its autonomous, AI-powered systems. Health In Tech (NASDAQ:HIT) – A pioneer in digital underwriting and quote-to-card technology for health insurance, transforming how plans are built and priced. Vita Bella – A wellness brand that continues to expand its national presence through health-focused lifestyle offerings. NRX Pharmaceuticals (NASDAQ:NRXP) – A late-stage pharmaceutical company advancing treatments for CNS disorders and respiratory distress. This week's featured corporate sponsors include: The Sustainable Green Team (OTC:SGTM) and its revolutionary Waterless Garden initiative for drought-resistant, sustainable landscaping. PetVivo Holdings, Inc. (NASDAQ:PETV), showcasing continued progress with its SPRYNG™, a veterinary injectable device for treating osteoarthritis in companion animals. Upcoming Highlights: New to The Street has also wrapped filming this week with several prominent brands: GLINT Pay (Private) – A disruptive gold-as-money platform allowing real-time gold transactions. Lahontan Gold Corp. (TSX.V:LG / OTCQB:LGCXF) – Canadian gold exploration company with high-grade assets in Nevada. Greer Consulting Group – Providing strategic solutions across regulatory compliance, M&A, and executive strategy. Special Feature Segment: A culinary showcase from two of New York City's most iconic dining destinations – Black Barn and Hunt & Fish Club – blending luxury hospitality with the business of restaurant branding. Additionally, special segments fromIMG Academy, Skip Barber Racing School, and KITON will continue to roll out in the coming months as part of New to The Street's ongoing coverage of elite performance, luxury, and innovation. Quote from Vince Caruso, Creator and Executive Producer of New to The Street: 'We continue to be a destination for innovative and publicly traded companies ready to tell their story at scale. Tonight's show blends AI, healthcare, crypto, and wellness with real national TV exposure. We're proud to feature these brands and grateful to our show sponsors for helping amplify their messages.' About New to The Street Since 2009, New to The Street has become one of the most trusted platforms for public and private companies to share their stories. The show combines sponsored programming with earned media, enhanced by iconic outdoor campaigns, nationwide TV commercials, and non-deal roadshows that connect executives with top-tier investors and institutions. With weekly reach across 220 million linear TV households, a growing 2.65 million YouTube subscribers, and a robust social media presence exceeding 700,000 followers across LinkedIn, Facebook, Instagram, and X, New to The Street delivers unparalleled exposure and credibility in the business media space. For more information, visit SOURCE: New To The Street View the original press release on ACCESS Newswire
Yahoo
43 minutes ago
- Yahoo
OKYO Pharma Limited's (NASDAQ:OKYO) market cap up US$38m last week, benefiting both individual investors who own 58% as well as insiders
OKYO Pharma's significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public 42% of the business is held by the top 12 shareholders Insider ownership in OKYO Pharma is 36% We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. A look at the shareholders of OKYO Pharma Limited (NASDAQ:OKYO) can tell us which group is most powerful. We can see that individual investors own the lion's share in the company with 58% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). Following a 58% increase in the stock price last week, individual investors profited the most, but insiders who own 36% stock also stood to gain from the increase. Let's take a closer look to see what the different types of shareholders can tell us about OKYO Pharma. View our latest analysis for OKYO Pharma Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index. As you can see, institutional investors have a fair amount of stake in OKYO Pharma. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of OKYO Pharma, (below). Of course, keep in mind that there are other factors to consider, too. We note that hedge funds don't have a meaningful investment in OKYO Pharma. Gabriele Marco Cerrone is currently the largest shareholder, with 29% of shares outstanding. For context, the second largest shareholder holds about 6.8% of the shares outstanding, followed by an ownership of 5.9% by the third-largest shareholder. Our studies suggest that the top 12 shareholders collectively control less than half of the company's shares, meaning that the company's shares are widely disseminated and there is no dominant shareholder. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage. While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it. Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group. Our information suggests that insiders maintain a significant holding in OKYO Pharma Limited. Insiders have a US$37m stake in this US$102m business. It is great to see insiders so invested in the business. It might be worth checking if those insiders have been buying recently. The general public, who are usually individual investors, hold a substantial 58% stake in OKYO Pharma, suggesting it is a fairly popular stock. This level of ownership gives investors from the wider public some power to sway key policy decisions such as board composition, executive compensation, and the dividend payout ratio. I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. To that end, you should learn about the 4 warning signs we've spotted with OKYO Pharma (including 2 which make us uncomfortable) . If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
an hour ago
- Yahoo
ExlService Holdings (NASDAQ:EXLS) Is Very Good At Capital Allocation
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for? One common approach is to try and find a company with returns on capital employed (ROCE) that are increasing, in conjunction with a growing amount of capital employed. Basically this means that a company has profitable initiatives that it can continue to reinvest in, which is a trait of a compounding machine. Speaking of which, we noticed some great changes in ExlService Holdings' (NASDAQ:EXLS) returns on capital, so let's have a look. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. If you haven't worked with ROCE before, it measures the 'return' (pre-tax profit) a company generates from capital employed in its business. To calculate this metric for ExlService Holdings, this is the formula: Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities) 0.20 = US$281m ÷ (US$1.7b - US$244m) (Based on the trailing twelve months to March 2025). Thus, ExlService Holdings has an ROCE of 20%. That's a fantastic return and not only that, it outpaces the average of 14% earned by companies in a similar industry. View our latest analysis for ExlService Holdings Above you can see how the current ROCE for ExlService Holdings compares to its prior returns on capital, but there's only so much you can tell from the past. If you'd like, you can check out the forecasts from the analysts covering ExlService Holdings for free. The trends we've noticed at ExlService Holdings are quite reassuring. The numbers show that in the last five years, the returns generated on capital employed have grown considerably to 20%. Basically the business is earning more per dollar of capital invested and in addition to that, 42% more capital is being employed now too. So we're very much inspired by what we're seeing at ExlService Holdings thanks to its ability to profitably reinvest capital. A company that is growing its returns on capital and can consistently reinvest in itself is a highly sought after trait, and that's what ExlService Holdings has. And with the stock having performed exceptionally well over the last five years, these patterns are being accounted for by investors. Therefore, we think it would be worth your time to check if these trends are going to continue. ExlService Holdings does have some risks though, and we've spotted 1 warning sign for ExlService Holdings that you might be interested in. If you want to search for more stocks that have been earning high returns, check out this free list of stocks with solid balance sheets that are also earning high returns on equity. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
